{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T13:15:17Z","timestamp":1655298917273},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1007\/s12185-011-0769-z","type":"journal-article","created":{"date-parts":[[2011,1,31]],"date-time":"2011-01-31T02:19:44Z","timestamp":1296440384000},"page":"243-246","source":"Crossref","is-referenced-by-count":3,"title":["Successful treatment with nilotinib after imatinib failure in a CML patient with a four-way Ph chromosome translocation and point mutations in BCR\/ABL gene"],"prefix":"10.1007","volume":"93","author":[{"given":"Masaya","family":"Okada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Satake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuji","family":"Kaida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Ikegame","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroya","family":"Tamaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Soma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Fujimori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyasu","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,2,1]]},"reference":[{"key":"769_CR1","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","volume":"340","author":"CL Sawyers","year":"1999","unstructured":"Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340:1330\u201340.","journal-title":"N Engl J Med"},{"key":"769_CR2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000132374","volume":"44","author":"M Braekeleer De","year":"1987","unstructured":"De Braekeleer M. Variant Philadelphia translocations in chronic myeloid leukemia. Cytogenet Cell Genet. 1987;44:215\u201322.","journal-title":"Cytogenet Cell Genet"},{"key":"769_CR3","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0165-4608(88)90314-7","volume":"32","author":"T Ishihara","year":"1988","unstructured":"Ishihara T, Minamihisamatsu M. The Philadelphia chromosome. Considerations based on studies of variant Ph translocations. Cancer Genet Cytogenet. 1988;32:75\u201392.","journal-title":"Cancer Genet Cytogenet"},{"key":"769_CR4","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000046636","volume":"107","author":"B Johansson","year":"2002","unstructured":"Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol. 2002;107:76\u201394.","journal-title":"Acta Haematol"},{"key":"769_CR5","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervanteset F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia. N Engl J Med. 2003;348:994\u20131004.","journal-title":"N Engl J Med"},{"key":"769_CR6","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"B Druker","year":"2006","unstructured":"Druker B, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408\u201317.","journal-title":"N Engl J Med"},{"key":"769_CR7","doi-asserted-by":"crossref","unstructured":"Silver RT, Talpaz M, Sawyers CL, Druker BJ, Hochhaus A, Schiffer CA, et al. Four years of follow-up of 1027 patients with late chronic phase (L-CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials. Blood. 2004;104:11a (abstract).","DOI":"10.1182\/blood.V104.11.23.23"},{"key":"769_CR8","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","volume":"94","author":"E Weisberg","year":"2006","unstructured":"Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD. AMN107 (nilotinib): a novel and selective inhibitor of BCR\u2013ABL. Br J Cancer. 2006;94:1765\u20139.","journal-title":"Br J Cancer"},{"key":"769_CR9","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","volume":"354","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Giles F, Wunderle L, Cowan-Jacob S, Ray A, Griffin JD. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354:2542\u201351.","journal-title":"N Engl J Med"},{"key":"769_CR10","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","volume":"110","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, et al. Nilotinib (formerly AMN107), a highly selective BCR\u2013ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110:3540\u20136.","journal-title":"Blood"},{"key":"769_CR11","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","volume":"111","author":"P le Coutre","year":"2008","unstructured":"le Coutre P, Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR\u2013ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood. 2008;111:1834\u20139.","journal-title":"Blood"},{"key":"769_CR12","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s12185-009-0327-0","volume":"89","author":"A Tojo","year":"2009","unstructured":"Tojo A, Usuki K, Urabe A, Maeda Y, Kobayashi Y, Jinnai I, et al. A phase I\/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed\/refractory Ph+ ALL. Int J Hematol. 2009;89:679\u201388.","journal-title":"Int J Hematol"},{"key":"769_CR13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1756-8722-1-15","volume":"1","author":"S Cang","year":"2008","unstructured":"Cang S, Liu D. P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia. J Hematol Oncol. 2008;1:15.","journal-title":"J Hematol Oncol"},{"key":"769_CR14","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1182\/blood-2008-04-154344","volume":"113","author":"E Jabbour","year":"2009","unstructured":"Jabbour E, Kantarjian HM, Jones D, Shan J, O\u2019Brien S, Reddy N, et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood. 2009;113:2154\u201360.","journal-title":"Blood"},{"key":"769_CR15","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in \u201cgood risk\u201d chronic granulocytic leukemia. Blood. 1984;63:789\u201399.","journal-title":"Blood"},{"key":"769_CR16","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"M Baccarani","year":"2006","unstructured":"Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809\u201320.","journal-title":"Blood"},{"key":"769_CR17","unstructured":"Mitelman F, Johansson B, Mertens F. Mitelman database of chromosome aberrations in cancer. 2010. http:\/\/cgap.nci.nih.gov\/Chromosomes\/Mitelman ."},{"key":"769_CR18","first-page":"99","volume":"20","author":"H Mkrtchyan","year":"2008","unstructured":"Mkrtchyan H, Ghazaryan S, Avetisyan G, Hovhannisyan A, Muradyan L, Daghbashyan S, et al. Novel complex t(V;9;22) rearrangements in three cases with chronic myeloid leukemia and a rare translocation in a case with classical Philadelphia chromosome. Oncol Rep. 2008;20:99\u2013104.","journal-title":"Oncol Rep"},{"key":"769_CR19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1365-2141.2004.04899.x","volume":"125","author":"MM El-Zimaity","year":"2004","unstructured":"El-Zimaity MM, Kantarjian H, Talpaz M, O\u2019Brien S, Giles F, Garcia-Manero G, et al. Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. Br J Haematol. 2004;125:187\u201395.","journal-title":"Br J Haematol"},{"key":"769_CR20","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/j.leukres.2009.01.011","volume":"33","author":"Y Zhao","year":"2009","unstructured":"Zhao Y, Wu G, Wu K, Liu L, Cao W, Yu X, et al. Simultaneous occurrence of variant Philadelphia translocations and ABL mutations in two patients with chronic myeloid leukemia. Leuk Res. 2009;33:e85\u20137.","journal-title":"Leuk Res"},{"key":"769_CR21","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.leukres.2007.01.009","volume":"31","author":"G Buda","year":"2007","unstructured":"Buda G, Orciuolo E, Cecconi N, Galimberti S, Cervetti G, Petrini M. Poor prognosis chronic myeloid leukemia with a complex variant Philadelphia translocation, t(9;10;22)(q34;q24;q11). Leuk Res. 2007;31:1765\u20136.","journal-title":"Leuk Res"},{"key":"769_CR22","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1080\/07357900802653498","volume":"27","author":"J Tan","year":"2009","unstructured":"Tan J, Cang S, Seiter K, Primanneni S, Ahmed N, Mathews T, et al. t(3;9;22) 3-way chromosome translocation in chronic myeloid leukemia is associated with poor prognosis. Cancer Invest. 2009;27:718\u201322.","journal-title":"Cancer Invest"},{"key":"769_CR23","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/blood-2002-09-2790","volume":"101","author":"JE Cortes","year":"2003","unstructured":"Cortes JE, Talpaz M, Giles F, O\u2019Brien S, Rios MB, Shan J, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood. 2003;101:3794\u2013800.","journal-title":"Blood"},{"key":"769_CR24","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood-2002-03-0777","volume":"100","author":"ME O\u2019Dwyer","year":"2002","unstructured":"O\u2019Dwyer ME, Mauro MJ, Kurilik G, Mori M, Balleisen S, Olson S, et al. The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood. 2002;100:1628\u201333.","journal-title":"Blood"},{"key":"769_CR25","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531\u201341.","journal-title":"N Engl J Med"},{"key":"769_CR26","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/BF03195613","volume":"49","author":"M Bara\u0144ska","year":"2008","unstructured":"Bara\u0144ska M, Lewandowski K, Gniot M, Iwo\u0142a M, Lewandowska M, Komarnicki M. Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR\u2013ABL oncogene. J Appl Genet. 2008;49:201\u20133.","journal-title":"J Appl Genet"},{"key":"769_CR27","unstructured":"Jakubowska J, Czyz M. Novel inhibitors of BCR\u2013Abl. Postepy Hig Med Dosw. 2006;60:697\u2013706 (Polish, online)."},{"key":"769_CR28","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1182\/blood-2005-12-010132","volume":"108","author":"N Bubnoff von","year":"2006","unstructured":"von Bubnoff N, Manley PW, Mestan J, Sanger J, Peschel C, Duyster J. BCR\u2013Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood. 2006;108:1328\u201333.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-011-0769-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-011-0769-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-011-0769-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T04:05:50Z","timestamp":1592280350000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-011-0769-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["769"],"URL":"https:\/\/doi.org\/10.1007\/s12185-011-0769-z","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}